QUOIN Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

ASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the second quarter ended June 30, 2026, before the market opens on Friday, August 14, 2026....

Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, with initiation expected in 2H 2026...

Quoin advances its U.S. patent protection with allowed claims supporting QRX003's investigational approach to treating Netherton Syndrome....

Quoin Pharmaceuticals receives FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome....

Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories...

Four of Six Patients Participating in the Compassionate Use Program Were Classified as 'Improved' or 'Significantly Improved' from Baseline Assessment Across Key Clinical Endpoints...

-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval-...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

-First ever IND submission for this disease, which has no current treatment or cure-...

LAS VEGAS, May 19, 2026 /PRNewswire/ -- The Netherton syndrome market size is expected to grow during the forecast period (2026–2036), primarily driven by the launch of upcoming therapies such as QRX003 (Quoin Pharmaceuticals), BCX17725 (BioCryst Pharmaceuticals), ATR-12 (Azitra), and......

– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome...

ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 7, 2026....

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications....

– Closes Private Placement Financing of Up to $104.5 Million...

FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S....

Midwestern banks to gain competitive edge with modern banking experiences MONETT, Mo., March 24, 2026 /PRNewswire/ -- Jack Henry® (Nasdaq: JKHY) announced today that Independent Bancshares Inc., the holding company of FM BANK and Quoin Financial Bank, has selected Jack Henry to strengthen......

ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026....

— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need —...

Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status...